GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy

BALTIMORE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics and consumer products today announced that it has completed the preclinical phase of assessing its novel neuropsychiatric cannabinoid therapy.

The Company had previously announced the preclinical study as part of its license and research agreement with Shaare Zedek Scientific related to the therapeutic developed by Dr. Adi Aran, renowned cannabinoid researcher. Dr. Aran will lead the clinical trial while Dr. Professor Tal Burstyn-Cohen, Ph.D. of the Hebrew University, through the Yissum Research Development Company, led the preclinical study. Professor Burstyn-Cohen’s lab is renowned for studying how microglia function in the regulation and maintenance of a healthy nervous system, and the consequences of any disruption of their function.

The preclinical study aimed to assess the impact of various combinations of the neuroprotective therapeutic in a preclinical model. The study’s in vitro data demonstrated neuroprotective attributes of the therapeutic. The study used the BV-2 mouse microglial cell line and LPS to induce an inflammatory response, and studied the signaling pathways involved in the anti-inflammatory, anti-oxidative and cytoprotective effects of the therapeutic compounds. In this model there was some, albeit minimal, synergism. However, it was found that there was a neuroprotective effect by both cannabidiol (CBD), as well as the other proprietary compounds used in the therapeutic.

Outcome measures that were evaluated include extracellular levels of proinflammatory cytokines, extracellular levels of nitrite to assess nitric oxide production, expression levels of genes and microRNAs known to be involved in inflammation and redox response, cellular levels of transcription factors and other proteins known to be involved in inflammation and redox response, and cellular levels of Reactive Oxygen Species (ROS). Markers of inflammation, redox state, and cell survival were assessed in resting state microglia and in cells that were stimulated with LPS, in each of the above conditions (a total of 164 experiments). Each experiment and assays were repeated multiple times.